Phio Pharmaceuticals Corp.
PHIO
$1.09
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 186.96% | 215.24% | 49.95% | 83.39% | 24.02% |
| Gross Profit | -186.96% | -215.24% | -49.95% | -83.39% | -24.02% |
| SG&A Expenses | -3.97% | 39.35% | 53.41% | 39.96% | 17.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.84% | 122.60% | 51.37% | 57.55% | 20.64% |
| Operating Income | -84.84% | -122.60% | -51.37% | -57.55% | -20.64% |
| Income Before Tax | -91.04% | -126.29% | -45.82% | -56.96% | -17.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.04% | -126.29% | -45.82% | -56.96% | -17.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.04% | -126.29% | -45.82% | -56.96% | -17.33% |
| EBIT | -84.84% | -122.60% | -51.37% | -57.55% | -20.64% |
| EBITDA | -84.84% | -122.60% | -51.31% | -57.50% | -20.67% |
| EPS Basic | 21.14% | 16.09% | 82.28% | 71.58% | 87.52% |
| Normalized Basic EPS | 21.15% | 16.09% | 82.29% | 71.58% | 87.52% |
| EPS Diluted | 21.14% | 16.09% | 82.28% | 71.58% | 87.52% |
| Normalized Diluted EPS | 21.15% | 16.09% | 82.29% | 71.58% | 87.52% |
| Average Basic Shares Outstanding | 142.28% | 169.71% | 722.96% | 452.38% | 839.81% |
| Average Diluted Shares Outstanding | 142.28% | 169.71% | 722.96% | 452.38% | 839.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |